한글목차

세계의 RNAi 기술 시장은 2024년에 11억 9,000만 달러로 평가되었고, 2030년에는 21억 4,000만 달러에 이를 전망이며, 예측 기간 동안 CAGR 10.28%로 확대될 것으로 예측됩니다.

RNA 간섭(RNAi)은 저분자 RNA를 통해 표적 유전자의 침묵을 가능하게 해, 바이오 기술 및 제약 분야에서 변혁 툴로서 등장했습니다. 이 메커니즘은 유전자 제어와 치료 혁신의 상황을 재형성하여 의약품 개발, 유전자 치료, 농업, 분자 연구에 응용되고 있습니다. 질환 관련 유전자를 선택적으로 저해하는 능력을 가진 RNAi는 암, 유전성 질환, 바이러스 감염 등의 복잡한 병태를 치료하기 위한 약제 파이프라인에 편입되는 경우가 많아지고 있습니다. 제약 회사는 높은 정확도, 적응성, 개별화 치료 개발의 가능성 때문에 RNAi 기반의 접근을 우선시하고 있습니다. 전달 시스템의 지속적인 진보와 RNAi 치료제 및 진단약에 대한 투자 증가가 맞물려 2030년까지 시장의 견조한 확대가 전망되고 있습니다.

시장 성장 촉진요인

RNAi 기반 치료제에 대한 수요 증가

주요 시장 과제

오프 타겟 효과

주요 시장 동향

정밀의료 및 개인화 치료

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 목소리

제5장 세계의 RNAi 기술 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율 및 예측
  • 유형별(마이크로 RNA, 저분자 간섭 RNA, 기타)
  • 용도별(치료 유형, 치료법, 약물전달, 농업, 기타)
  • 최종 사용자별(연구 및 학술기관, 진단기관, 기타)
  • 기업별(2024년)
  • 지역별
• 시장 맵

제6장 북미의 RNAi 기술 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제7장 유럽의 RNAi 기술 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 RNAi 기술 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 한국
  • 일본
  • 호주

제9장 남미의 RNAi 기술 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 RNAi 기술 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향 및 발전

• 최근 동향
• 제품 출시
• 합병 및 인수

제13장 세계의 RNAi 기술 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

• 업계 내 경쟁
• 신규 진입의 가능성
• 공급자의 힘
• 고객의 힘
• 대체품의 위협

제15장 경쟁 구도

• Alnylam Pharmaceuticals, Inc
• Ionis Pharmaceuticals, Inc.
• Atalanta Therapeutics
• Phio Pharmaceuticals
• Benitec Biopharma
• Novartis AG
• AstraZeneca
• Silence Therapeutics
• Arbutus Biopharma
• Sylentis SA

제16장 전략적 제안

제17장 기업 소개 및 면책사항

영문목차

The Global RNAi Technology Market was valued at USD 1.19 billion in 2024 and is projected to reach USD 2.14 billion by 2030, expanding at a CAGR of 10.28% during the forecast period. RNA interference (RNAi) has emerged as a transformative tool in the biotechnology and pharmaceutical sectors, enabling targeted gene silencing through small RNA molecules. This mechanism has reshaped the landscape of gene regulation and therapeutic innovation, finding applications across drug development, gene therapy, agriculture, and molecular research. With its ability to selectively inhibit disease-related genes, RNAi is increasingly being integrated into drug pipelines for treating complex conditions such as cancer, genetic disorders, and viral infections. Pharmaceutical companies are prioritizing RNAi-based approaches due to their high precision, adaptability, and potential for developing personalized treatments. The continuous advancements in delivery systems, coupled with growing investments in RNAi therapeutics and diagnostics, are expected to drive robust market expansion through 2030.

Key Market Drivers

Growing Demand for RNAi-based Therapeutics

The rising demand for RNAi-based therapeutics plays a critical role in propelling the growth of the global RNAi technology market. RNAi enables highly targeted treatment by silencing genes that contribute to the progression of chronic and genetic diseases, such as certain cancers, viral infections, and neurodegenerative conditions. As the global prevalence of such disorders continues to rise, there is a growing need for precise and less invasive treatment options. RNAi-based drugs support a personalized medicine approach, tailoring therapies based on individual genetic profiles and minimizing off-target effects. The successful commercialization of RNAi therapies, such as Onpattro, has strengthened confidence in the clinical viability of these treatments, encouraging more companies to invest in research and development. Furthermore, RNAi's utility in functional genomics and target validation makes it a valuable tool in drug discovery, reinforcing its expanding role across both therapeutic and research domains.

Key Market Challenges

Off-Target Effects

Off-target gene silencing presents a major obstacle to the widespread adoption of RNAi technology. Although RNAi is known for its precision, unintended interactions with non-target genes can lead to undesired cellular responses, including toxicity or immune reactions. These safety concerns require extensive preclinical and clinical validation, increasing development time and costs. Designing RNAi molecules with high specificity remains a complex task, particularly when targeting genes in complex biological systems. Off-target effects not only compromise therapeutic outcomes but also affect research accuracy in functional genomics. Addressing this challenge involves improving RNA sequence design, refining delivery mechanisms, and enhancing regulatory oversight to ensure the safe application of RNAi in both clinical and research settings.

Key Market Trends

Precision Medicine and Personalized Therapies

The integration of RNAi technology into precision medicine is a significant trend shaping the future of the healthcare industry. As personalized therapies become increasingly important, RNAi's ability to silence specific genetic mutations makes it an ideal platform for individualized treatment strategies. In oncology, for instance, RNAi-based therapies are being developed to target genetic mutations unique to different tumor types, offering greater efficacy and reduced side effects compared to conventional therapies. This alignment with personalized medicine is also driving partnerships and R&D efforts focused on developing tailored RNAi-based solutions. By enabling gene-specific modulation, RNAi supports the broader shift toward customized, data-driven healthcare approaches.

Key Market Players

• Alnylam Pharmaceuticals, Inc
• Ionis Pharmaceuticals, Inc.
• Atalanta Therapeutics
• Phio Pharmaceuticals
• Benitec Biopharma
• Novartis AG
• AstraZeneca
• Silence Therapeutics
• Arbutus Biopharma
• Sylentis S.A.

Report Scope:

In this report, the Global RNAi Technology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

RNAi Technology Market, By Type:

• Micro RNA
• Small interfering RNA
• Others

RNAi Technology Market, By Application:

• Treatment Type
• Therapeutics
• Drug Delivery
• Agriculture
• Others

RNAi Technology Market, By End User:

• Research and Academic Laboratories
• Diagnostic Laboratories
• Others

RNAi Technology Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global RNAi Technology Market.

Available Customizations:

Global RNAi Technology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global RNAi Technology Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Micro RNA, Small interfering RNA, Others)
  • 5.2.2. By Application (Treatment Type, Therapeutics, Drug Delivery, Agriculture, Others)
  • 5.2.3. By End User (Research and Academic Laboratories, Diagnostic Laboratories, Others)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America RNAi Technology Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States RNAi Technology Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Mexico RNAi Technology Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Canada RNAi Technology Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe RNAi Technology Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France RNAi Technology Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany RNAi Technology Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom RNAi Technology Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy RNAi Technology Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain RNAi Technology Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia-Pacific RNAi Technology Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China RNAi Technology Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India RNAi Technology Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. South Korea RNAi Technology Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. Japan RNAi Technology Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia RNAi Technology Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. South America RNAi Technology Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil RNAi Technology Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina RNAi Technology Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia RNAi Technology Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. Middle East and Africa RNAi Technology Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa RNAi Technology Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia RNAi Technology Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE RNAi Technology Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global RNAi Technology Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Alnylam Pharmaceuticals, Inc
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (In case of listed)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Ionis Pharmaceuticals, Inc.
• 15.3. Atalanta Therapeutics
• 15.4. Phio Pharmaceuticals
• 15.5. Benitec Biopharma
• 15.6. Novartis AG
• 15.7. AstraZeneca
• 15.8. Silence Therapeutics
• 15.9. Arbutus Biopharma
• 15.10. Sylentis S.A.

16. Strategic Recommendations

17. About Us & Disclaimer